MedPath

Methylene blue dye in the evaluation of the primary draining lymph nodes in localised, node-negative oral cavity cancer: a prospective study from a tertiary cancer center.

Not Applicable
Not yet recruiting
Conditions
Health Condition 1: C060- Malignant neoplasm of cheek mucosa
Registration Number
CTRI/2022/01/039523
Lead Sponsor
Kidwai Memorial Institute of Oncology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Consecutive patients with biopsy proven, upfront operable SCC of the buccal mucosa, with no clinical or radiological evidence of cervical lymphadenopathy.

Exclusion Criteria

Patients who were under 18 years of age, oral cavity subsites other than buccal mucosa, with prior history of head and neck surgery, recurrent oral cancer or any form of neoadjuvant therapy, patients with palpable lymphadenopathy and those who did not consent to the procedure

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pattern of lymph nodal spread in buccal mucosa SCC <br/ ><br>SLN identification rate with blue dye <br/ ><br>The accuracy (including the true positive and false negative rate) of blue dye in predicting the nodal status of the neck.Timepoint: 8 weeks (at study completion)
Secondary Outcome Measures
NameTimeMethod
Incidence of nodal metastases in clinically node negative SCC of the buccal mucosa <br/ ><br>Identification and correlation of tumor factors predictive of nodal involvement.Timepoint: 4 weeks
© Copyright 2025. All Rights Reserved by MedPath